potassium methoxide-methanol | 63425-22-9

• 分子结构分类: 有机化合物 - 有机盐 - 有机金属盐
• 英文名称: potassium methoxide-methanol
• 英文别名: Potassium methoxide methanol；potassium;methanol;methanolate
• CAS: 63425-22-9
• 化学式: CH₃O*CH₄O*K
• 分子量: 102.175
• InChiKey: IXQYZUOOHQWOQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -4.41
• 重原子数：
  5
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  43.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dicyclopentadienyl(tetrahydrofurane)yttrium chloride 、 potassium methoxide-methanol 以 四氢呋喃 为溶剂， 生成 dicyclopentadienylyttrium methoxide
  参考文献：
  名称：

  可溶性五金属有机钇醇盐氧化物复合物 (C5H5)5Y5(.mu.-OCH3)4(.mu.5-O) 的合成和 X 射线晶体结构

  摘要：

  作为制造氧稳定的有机钇和有机镧系元素配合物的一般计划的一部分，他们研究了简单原型有机金属醇盐配合物二环戊二烯基三甲醇盐 (1) 的合成路线。虽然 1 可以在 ((C/sub 5/H/sub 5/)/sub 28/..mu..-H)(THF))/sub 2/ 与 CH/sub 3/OH 的反应中产生或CH/sub 2/O，从 (C/sub 5/H/sub 5/)/sub 2/YCl(THF) 和碱金属甲醇盐的潜在更直接的合成可以采取不同的过程。可以获得一种显着的多金属氧化物复合物，其合成和结构可能对有机金属氧化物/醇盐化学具有重要意义。(C/sub 5/H/sub 5/)/sub 2/YCl(THF) 与去溶剂化的 KOCH/sub 3/ 在 THF 中在 30/sup 0/C 下反应过夜，形成含有一些二环戊二烯基甲醇三甲酯的混合物。通过使用溶剂化物 KOCH/sub 3/ x CH/sub

  DOI：

  10.1021/ja00279a100

文献信息

• Process for preparing n-alkyllactams
  申请人：Huels Aktiengesellschaft

  公开号：US05508396A1

  公开（公告）日：1996-04-16

  A process for preparing an N-alkyllactam, comprising the steps of: (a) reacting a lactam with an alkali metal alkoxide at 130.degree.-170.degree. C. and removing the alcohol formed by distillation; (b) reacting the product from step (a), if desired in a mixture with the product from step (e), with an alkyl halide in a solvent which is (i) an ethylene glycol dialkyl ether of the formula R--O--(CH.sub.2 --CH.sub.2 --O).sub.m R, where R in C.sub.1 -C.sub.4 -alkyl and m is 1-8, (ii) the N-alkyllactam to be prepared or (iii) a mixture of (i) and (ii), to obtain crude N-alkylactam or an alkali metal salt; (c) separating the alkali metal salt from the crude N-alkylactam; (d) subjecting the N-alkyllactam crude product to high-purity distillation after addition of a sufficient amount of alkali metal alkoxide to convert any unreacted lactam to a salt; and (e) recycling the bottom product of the distillation in step (d) in step (e) into step (b), is environmentally friendly and affords the desired N-alkyllactam in high yield and high purity.

  一种制备N-烷基内酰胺的方法，包括以下步骤：(a)在130℃-170℃下将内酰胺与碱金属醇盐反应，并通过蒸馏去除生成的醇；(b)将步骤(a)的产物（如果需要与步骤(e)的产物混合）与烷基卤代物在溶剂中反应，所述溶剂为(i)具有以下式子的乙二醇双烷基醚R-O-(CH2- -O)mR，其中R为C1-C4烷基，m为1-8，(ii)待制备的N-烷基内酰胺，或(iii) (i)和(ii)的混合物，以获得粗N-烷基内酰胺或碱金属盐；(c)将碱金属盐与粗N-烷基内酰胺分离；(d)在加入足够量的碱金属醇盐将未反应的内酰胺转化为盐之后，将N-烷基内酰胺粗产品经高纯度蒸馏处理；(e)将蒸馏步骤(d)的底部产物回收到步骤(b)中，该方法环保且产率高，纯度高，能够得到所需的N-烷基内酰胺。
• ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS
  申请人：Baindur Nand

  公开号：US20060281772A1

  公开（公告）日：2006-12-14

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R 1 , R 2 , R 3 , B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  该发明涉及公式I的烷基喹啉和烷基喹唑啉化合物：其中R1、R2、R3、B、Z、G、Q和X如本文所定义，使用这些化合物作为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，使用这些化合物来减少或抑制细胞或受体中FLT3和/或c-kit和/或TrkB的激酶活性，以及使用这些化合物来预防或治疗细胞增殖性疾病和/或与FLT3和/或c-kit和/或TrkB相关的疾病。本发明还涉及包含本发明化合物的制药组合物和用于治疗癌症和其他细胞增殖性疾病的方法。
• Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines
  申请人：Baumann Andrew Christian

  公开号：US20070004660A1

  公开（公告）日：2007-01-04

  The invention is directed to a method of inhibiting FLT3 tyrosine kinase activity or expression or reducing FLT3 kinase activity or expression in a cell or a subject comprising the administration of a farnesyl transferase inhibitor and a FLT3 kinase inhibitor selected from alkylquinoline and alkylquinazoline compounds of Formula I′: where R 1 , R 2 , R 3 , Z, G, Q and X are as defined herein. Included within the present invention is both prophylactic and therapeutic methods for treating a subject at risk of (or susceptible to) developing a cell proliferative disorder or a disorder related to FLT3.

  本发明涉及一种抑制细胞或主体中FLT3酪氨酸激酶活性或表达或减少FLT3激酶活性或表达的方法，包括给予一种法尼酰转移酶抑制剂和一种从式I'的烷基喹啉和烷基喹唑啉化合物中选择的FLT3激酶抑制剂：其中R1、R2、R3、Z、G、Q和X如本文所定义。本发明包括治疗和预防方法，用于治疗或预防患有细胞增殖性疾病或与FLT3相关的疾病的患者。
• INTERMEDIATES USEFUL IN THE SYNTHESIS OF ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS, AND RELATED METHODS OF SYNTHESIS
  申请人：Baindur Nand

  公开号：US20070021436A1

  公开（公告）日：2007-01-25

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C: wherein R 1 , R 2 , R 99 , and X are as defined herein, the use of such compounds in the sysnthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.

  本发明涉及公式C的烷基喹啉和烷基喹唑啉化合物，其中R1，R2，R99和X如本文所定义，以及在合成蛋白酪氨酸激酶抑制剂，特别是FLT3和/或c-kit和/或TrkB抑制剂中使用这些化合物的方法。
• Alkylquinoline and alkylquinazoline kinase modulators
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US08071768B2

  公开（公告）日：2011-12-06

  The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula I: wherein R1, R2, R3, B, Z, G, Q and X are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of FLT3 and/or c-kit and/or TrkB, the use of such compounds to reduce or inhibit kinase activity of FLT3 and/or c-kit and/or TrkB in a cell or a subject, and the use of such compounds for preventing or treating in a subject a cell proliferative disorder and/or disorders related to FLT3 and/or c-kit and/or TrkB. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as cancers and other cell proliferative disorders.

  本发明涉及式I的烷基喹啉和烷基喹唑啉化合物：其中R1、R2、R3、B、Z、G、Q和X如本文所定义，以及使用这些化合物作为蛋白酪氨酸激酶调节剂，特别是FLT3和/或c-kit和/或TrkB的抑制剂，使用这些化合物来减少或抑制细胞或主体中FLT3和/或c-kit和/或TrkB的激酶活性，以及使用这些化合物预防或治疗主体中细胞增殖性疾病和/或与FLT3和/或c-kit和/或TrkB有关的疾病。本发明还涉及包含本发明化合物的药物组合物以及治疗癌症和其他细胞增殖性疾病的方法。